CEBPB and glioblastoma: Lucicebtide (previously referred to as ST101) is a peptide antagonist of C/EBPβ (18) that is currently Phase 3-ready following completion of a Phase 2 study in patients with GBM (Clinicaltrials.gov ID: NCT04478279).